A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China

Genomics

Volumn 97, Issue 5, 2011, Pages 277-281

  Xiong, Yuyu ^a,b   Wang, Ming ^a   Fang, Ke ^a   Xing, Qinghe ^c   Feng, Guoyin ^d   Shen, Lu ^a,b   He, Lin ^a,c   Qin, Shengying ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

CYP2C9; Han; Mainland china; Pharmacogenomics; Polymorphism

Indexed keywords

CYTOCHROME P450 2C9; MESSENGER RNA;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CHINA; CONTROLLED STUDY; CYP2C9 GENE; DNA FLANKING REGION; DNA SEQUENCE; EXON; FEMALE; GENE; GENE DELETION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INTRON; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PRIORITY JOURNAL; VOLUNTEER;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; EXONS; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; INTRONS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 79955507772     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2010.11.004     Document Type: Article

References (32)

1. Oinonen T., Lindros K. Zonation of hepatic cytochrome P-450 expression and regulation. The Biochemical Journal 1998, 329:17-35.
2. Bertz R., Granneman G. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics 1997, 32:210-258.
3. Evans W., Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
4. Rendic S., Carlo F.D. Human cytochrome P450 enzymes: a status report, summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews 1997, 29:413-580.
5. Zhou, S.-F., Z.-W. Zhou, and M. Huang, Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology, 278 (2010) 165-188.
6. Kidd R.S., et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999, 9:71-80.
7. Rettie A.E., et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994, 4:39-42.
8. Miners J., Birkett D. Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology 1998, 45:525-538.
9. Thijssen H.H., Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clinical Pharmacology and Therapeutics 2003, 74:61-68.
10. Takahashi H., et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998, 8:365-373.
11. Yasar U., et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochemical and Biophysical Research Communications 1999, 254:628-631.
12. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6:341-349.
13. Zand N., et al. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy iranian population. Clinical and Experimental Pharmacology & Physiology 2007, 34:102-105.
14. Shi Y., et al. Genetic structure adds power to detect schizophrenia susceptibility at SLIT3 in the Chinese Han population. Genome Research 2004, 14:1345-1349.
15. Scott S.A., et al. CYP2C9*8 is prevalent among African-American implications for pharmacogenetic dosing. Pharmacogenomics 2009, 10(8):1243-1255.
16. Scott S.A., et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010, 11(6):781-791.
17. Blaisdell J., et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004, 14(8):527-537.
18. Allabi A., Gala J., Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenetics and Genomics 2005, 15(11):779-786.
19. Yang J.Q., et al. Frequency of cytochrome P450 2C9 allelicvariants in the Chinese and French populations. Fundamental & Clinical Pharmacology 2003, 17:373-376.
20. Adithan C., et al. Allele and genotype frequency of CYP2C9 in Tamilnadu population. European Journal of Clinical Pharmacology 2003, 59:707-709.
21. Jose R., et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population 2004, 19:101-105. Blackwell Publishing Fundamental & Clinical Pharmacology.
22. Nasu K., Kubota T., Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997, 7:405-409.
23. Yoon Y.-R., et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001, 51:277-280. Blackwell Science Ltd.
24. Allabi A.C., et al. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003, 56:653-657. Blackwell Publishing Ltd.
25. HA N., et al. CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Medical Journal 2009, 50(5):490-493.
26. Hamdy S.I., et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002, 53:596-603. Blackwell Science Ltd.
27. Dickmann L., et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Molecular Pharmacology 2001, 60:382-387.
28. Stubbins M., et al. Genetic analysis of the human cytochrome P-450 CYP2C9 locus. Pharmacogenetics 1996, 6:429-439.
29. Dorado P., et al. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. European Journal of Clinical Pharmacology 2003, 59:221-225.
30. Scordo M.G., et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacological Research 2004, 50:195-200.
31. Aynacioglu A.S., et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999, 48:409-415. Blackwell Science Ltd.
32. Scott S.A., et al. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics 2007, 8:721-730.